Technical Analysis for XNCR - Xencor, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Up 3 Days in a Row | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 1.10% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.10% | |
| Outside Day | Range Expansion | 1.10% | |
| Oversold Stochastic | Weakness | 1.10% | |
| Outside Day | Range Expansion | 4.68% | |
| Oversold Stochastic | Weakness | 4.68% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 5.60% |
| Alert | Time |
|---|---|
| Up 3% | about 7 hours ago |
| Up 2% | about 7 hours ago |
| Up 1% | about 8 hours ago |
| Rose Above Previous Day's High | about 9 hours ago |
| 10 DMA Resistance | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/06/2024
Xencor, Inc. Description
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Immunology Immune System Antibodies Autoimmune Disease Monoclonal Antibodies Antibody Rheumatoid Arthritis Asthma Glycoproteins Lupus Treatment Of Autoimmune Disease Antibody Product Catalent Immunoglobulin E
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.96 |
| 52 Week Low | 16.49 |
| Average Volume | 696,096 |
| 200-Day Moving Average | 20.94 |
| 50-Day Moving Average | 22.01 |
| 20-Day Moving Average | 20.22 |
| 10-Day Moving Average | 19.07 |
| Average True Range | 0.93 |
| RSI (14) | 39.39 |
| ADX | 31.63 |
| +DI | 15.48 |
| -DI | 26.70 |
| Chandelier Exit (Long, 3 ATRs) | 19.89 |
| Chandelier Exit (Short, 3 ATRs) | 20.74 |
| Upper Bollinger Bands | 22.82 |
| Lower Bollinger Band | 17.61 |
| Percent B (%b) | 0.31 |
| BandWidth | 25.73 |
| MACD Line | -0.93 |
| MACD Signal Line | -0.84 |
| MACD Histogram | -0.0931 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.36 | ||||
| Resistance 3 (R3) | 21.29 | 20.52 | 21.01 | ||
| Resistance 2 (R2) | 20.52 | 19.97 | 20.55 | 20.89 | |
| Resistance 1 (R1) | 19.87 | 19.64 | 20.20 | 19.94 | 20.77 |
| Pivot Point | 19.10 | 19.10 | 19.26 | 19.13 | 19.10 |
| Support 1 (S1) | 18.45 | 18.55 | 18.78 | 18.52 | 17.69 |
| Support 2 (S2) | 17.68 | 18.22 | 17.71 | 17.57 | |
| Support 3 (S3) | 17.03 | 17.68 | 17.46 | ||
| Support 4 (S4) | 17.10 |
